Sumitomo Mitsui DS Asset Management Company Ltd Purchases 61 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Sumitomo Mitsui DS Asset Management Company Ltd lifted its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 1.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,892 shares of the biotechnology company’s stock after purchasing an additional 61 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in United Therapeutics were worth $856,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Comerica Bank boosted its holdings in United Therapeutics by 2,697.2% in the third quarter. Comerica Bank now owns 156,587 shares of the biotechnology company’s stock valued at $35,368,000 after acquiring an additional 150,989 shares during the last quarter. Pacer Advisors Inc. boosted its holdings in United Therapeutics by 27.6% in the fourth quarter. Pacer Advisors Inc. now owns 312,799 shares of the biotechnology company’s stock valued at $68,781,000 after acquiring an additional 67,738 shares during the last quarter. Caisse DE Depot ET Placement DU Quebec boosted its holdings in United Therapeutics by 30.9% in the third quarter. Caisse DE Depot ET Placement DU Quebec now owns 260,412 shares of the biotechnology company’s stock valued at $58,819,000 after acquiring an additional 61,543 shares during the last quarter. Glenmede Trust Co. NA boosted its holdings in United Therapeutics by 840.1% in the third quarter. Glenmede Trust Co. NA now owns 68,098 shares of the biotechnology company’s stock valued at $15,381,000 after acquiring an additional 60,854 shares during the last quarter. Finally, Robeco Institutional Asset Management B.V. boosted its holdings in United Therapeutics by 125.2% in the third quarter. Robeco Institutional Asset Management B.V. now owns 87,048 shares of the biotechnology company’s stock valued at $19,662,000 after acquiring an additional 48,397 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

UTHR has been the topic of several analyst reports. Wells Fargo & Company upped their target price on United Therapeutics from $309.00 to $325.00 and gave the company an “overweight” rating in a report on Thursday, March 7th. The Goldman Sachs Group raised United Therapeutics from a “sell” rating to a “neutral” rating and boosted their price target for the company from $213.00 to $215.00 in a research note on Monday, February 12th. Wedbush reissued an “outperform” rating and issued a $308.00 price target on shares of United Therapeutics in a research note on Thursday, February 22nd. SVB Leerink assumed coverage on United Therapeutics in a research note on Monday, February 5th. They issued an “outperform” rating and a $330.00 price target on the stock. Finally, StockNews.com lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 11th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $294.25.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $235.95 on Friday. The company has a quick ratio of 4.28, a current ratio of 4.41 and a debt-to-equity ratio of 0.05. United Therapeutics Co. has a twelve month low of $204.44 and a twelve month high of $261.54. The stock’s 50 day moving average is $233.36 and its 200-day moving average is $228.79. The firm has a market capitalization of $11.10 billion, a price-to-earnings ratio of 11.89 and a beta of 0.52.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share for the quarter, topping analysts’ consensus estimates of $4.28 by $0.08. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The company had revenue of $614.70 million for the quarter, compared to analyst estimates of $575.01 million. During the same period in the prior year, the firm earned $2.67 earnings per share. United Therapeutics’s revenue for the quarter was up 25.1% on a year-over-year basis. Sell-side analysts forecast that United Therapeutics Co. will post 23.45 EPS for the current fiscal year.

Insider Transactions at United Therapeutics

In related news, EVP Paul A. Mahon sold 6,000 shares of the company’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $215.01, for a total transaction of $1,290,060.00. Following the completion of the sale, the executive vice president now owns 36,599 shares in the company, valued at $7,869,150.99. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, CEO Martine A. Rothblatt sold 15,000 shares of the company’s stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $236.59, for a total transaction of $3,548,850.00. Following the completion of the sale, the chief executive officer now owns 130 shares in the company, valued at $30,756.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Paul A. Mahon sold 6,000 shares of the company’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $215.01, for a total value of $1,290,060.00. Following the sale, the executive vice president now owns 36,599 shares of the company’s stock, valued at approximately $7,869,150.99. The disclosure for this sale can be found here. Insiders have sold 136,990 shares of company stock valued at $32,239,641 over the last ninety days. 12.50% of the stock is owned by company insiders.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.